Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018146116) IN VIVO STABLE HG-197(M) COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF IN NUCLEAR MEDICAL DIAGNOSTICS AND ENDORADIONUCLIDE THERAPY (THERANOSTICS)
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/146116 International Application No.: PCT/EP2018/052996
Publication Date: 16.08.2018 International Filing Date: 07.02.2018
IPC:
C07B 59/00 (2006.01) ,C07F 3/12 (2006.01)
[IPC code unknown for C07B 59][IPC code unknown for C07F 3/12]
Applicants:
HELMHOLTZ-ZENTRUM DRESDEN - ROSSENDORF E.V. [DE/DE]; Bautzner Landstraße 400 01328 Dresden, DE
Inventors:
PIETZSCH, Hans-Jürgen; DE
WALTHER, Martin; DE
WÜNSCHE, Thomas; DE
Agent:
KAILUWEIT & UHLEMANN PATENTANWÄLTE PARTNERSCHAFT MBB; Bamberger Straße 49 01187 Dresden, DE
Priority Data:
17155213.608.02.2017EP
Title (EN) IN VIVO STABLE HG-197(M) COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF IN NUCLEAR MEDICAL DIAGNOSTICS AND ENDORADIONUCLIDE THERAPY (THERANOSTICS)
(FR) COMPOSÉS DE HG-197(M) STABLES IN VIVO, PROCÉDÉ DE PRODUCTION ASSOCIÉ ET UTILISATION ASSOCIÉE EN DIAGNOSTIC MEDICAL NUCLÉAIRE ET EN THÉRAPIE UTILISANT DES ENDORADIONUCLÉIDES (THÉRANOSTIC)
Abstract:
(EN) The present invention relates to in vivo stable 197(m)Hg compounds according to formula (I) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the 197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA 197(m)Hg by electrophilic substitution; and the use of the 197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer.
(FR) La présente invention concerne des composés de 197(m)Hg stables in vivo de formule (I) pour une utilisation en diagnostic médical nucléaire et en thérapie utilisant des endoradionucléides (théranostic), en particulier pour le traitement du cancer, un procédé de production des composés de 197(m)Hg comprenant l'étape de radiomarquage de composés précurseurs organiques avec du 197(m)Hg NCA par substitution électrophile ; et l'utilisation de composés de 197(m)Hg pour un diagnostic médical nucléaire et une thérapie par des endoradionucléides (théranostic), en particulier pour le traitement du cancer.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)